Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Accumulated Expenses: 2013-2024

Historic Accumulated Expenses for Ocular Therapeutix (OCUL) over the last 12 years, with Dec 2024 value amounting to $35.1 million.

  • Ocular Therapeutix's Accumulated Expenses rose 32.25% to $40.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.3 million, marking a year-over-year increase of 32.25%. This contributed to the annual value of $35.1 million for FY2024, which is 22.50% up from last year.
  • Ocular Therapeutix's Accumulated Expenses amounted to $35.1 million in FY2024, which was up 22.50% from $28.7 million recorded in FY2023.
  • In the past 5 years, Ocular Therapeutix's Accumulated Expenses registered a high of $35.1 million during FY2024, and its lowest value of $14.3 million during FY2020.
  • Over the past 3 years, Ocular Therapeutix's median Accumulated Expenses value was $28.7 million (recorded in 2023), while the average stood at $29.3 million.
  • Data for Ocular Therapeutix's Accumulated Expenses shows a peak YoY surged of 87.39% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Ocular Therapeutix's Accumulated Expenses stood at $14.3 million in 2020, then spiked by 40.64% to $20.1 million in 2021, then climbed by 19.76% to $24.1 million in 2022, then increased by 18.96% to $28.7 million in 2023, then climbed by 22.50% to $35.1 million in 2024.